R&D Rare Disease Day: Enhancing clinical trial success in rare d... Rare diseases impact an estimated 300 million people globally, while around one in five cancers are considered a rare disease.
News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
